The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients.

摘要: The purpose of the study was to evaluate influence baseline haemoglobin level in predicting response 5-fluorouracil (5FU)-based first-line chemotherapy advanced colorectal cancer patients. Data from 631 patients were collected three different institutions. Globally, overall rate 35.8% (226 out 631). Factors influencing 5FU dose intensity (high: 43.1%, low: 34.0%, P=0.03); oxaliplatin (yes: 45.8%, no: 22.9%, P<0.0001), performance status (PS 0: 46.1%, 1: 28.8%, 2: 26.7%, and levels (⩾12 g dl−1: 40.4%, <12 g dl−1: 29.2%, P=0.004). In subgroup analysis significant differences between anaemic nonanaemic recorded those treated with infusional chemotherapies (45.7 vs 25.5%, high (50.3 32.7%, P=0.005), PS=0 (49.8 37.9%, P=0.03), liver metastases (44.8 33.8%, P=0.002), whereas no difference evident subjects bolus schedules or according gender. Anaemia a strong predictor for activity 5FU-based especially groups that showed best responses, example status, infusionally treated, higher secondaries. Patients greater longer time progression survival than subjects. Prospective evaluation role correcting anaemia on therapy is justified by these results.